Thrivent Financial for Lutherans Sells 6,575 Shares of Amgen Inc. $AMGN

Thrivent Financial for Lutherans trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 546,037 shares of the medical research company’s stock after selling 6,575 shares during the period. Thrivent Financial for Lutherans’ holdings in Amgen were worth $178,750,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMGN. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the period. Board of the Pension Protection Fund bought a new stake in Amgen during the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its holdings in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter valued at about $33,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on AMGN shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research report on Wednesday, April 8th. Rothschild & Co Redburn upped their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group started coverage on shares of Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. Finally, Barclays started coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $356.15.

Amgen Stock Performance

NASDAQ:AMGN opened at $336.23 on Friday. Amgen Inc. has a 12-month low of $264.15 and a 12-month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $181.46 billion, a PE ratio of 23.40, a price-to-earnings-growth ratio of 3.38 and a beta of 0.44. The firm has a 50-day moving average price of $350.23 and a 200 day moving average price of $343.11.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the prior year, the business posted $4.90 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.36 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.